Drug Trial Radar · NCT03918915
The Safety and Efficacy of SYD-101 in Children With Myopia
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
852
Actual
Start
Apr 24, 2019
Primary completion
May 2, 2024
Study completion May 1, 2025
Sponsor
- Lead sponsor
- Sydnexis, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Early treatment of myopia in children could help slow the condition and minimize the risk of complications later in life. This study investigates the use of SYD-101, an eye solution, in slowing-down the progression of myopia in children.
Conditions
- Nearsightedness
- Near Sightedness
- Near-sightedness
Interventions
SYD-101 0.01%Drug
Sterile topical ophthalmic solution
SYD-101 0.03%Drug
Sterile topical ophthalmic solution
VehicleDrug
Sterile topical ophthalmic solution without active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Myopic Progression <-0.75 D (Diopters)Time frame: Month 36
Locations
47 sites in 3 countries. Site status is shown where the registry gives one.
Site 143
Irwindale, California
Site 144
Pasadena, California
Site 148
San Diego, California
Site 104
San Diego, California
Site 110
Santa Barbara, California
Site 133
Sunnyvale, California
Site 130
Colorado Springs, Colorado
Site 100
Fort Collins, Colorado
Site 102
Danbury, Connecticut
Site 150
Waterbury, Connecticut
Site 122
Fort Lauderdale, Florida
Site 109
Jupiter, Florida
Site 119
Sweetwater, Florida
Site 120
Tamarac, Florida
Site 124
Marietta, Georgia
Site 116
Chicago, Illinois
Site 106
Wilmette, Illinois
Site 135
Indianapolis, Indiana
Site 131
Munster, Indiana
Site 137
Pittsburg, Kansas
Site 138
Bangor, Maine
Site 123
Boston, Massachusetts
Site 114
Washington, Missouri
Site 132
Henderson, Nevada
Site 139
Albuquerque, New Mexico
Site 127
Buffalo, New York
Site 117
Chapel Hill, North Carolina
Site 121
Raleigh, North Carolina
Site 105
Fargo, North Dakota
Site 111
Medford, Oregon
Site 147
Tigard, Oregon
Sie 136
Bala-Cynwyd, Pennsylvania
Site 128
Cranberry Township, Pennsylvania
Site 108
Charleston, South Carolina
Site 126
Lakeway, Texas
Site 142
San Antonio, Texas
Site 101
San Antonio, Texas
Site 115
The Woodlands, Texas
Site 149
Ogden, Utah
Site 140
Ogden, Utah
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.